Le translationnel, de l'essai TAMRAD à l'essai CHIVA: Continuum entre recherche fondamentale et cliniqueALEXANDRE, Jérôme; BACHELOT, Thomas.Onko +. 2012, Vol 4, Num 34, pp 8-9, issn 2101-9495, 2 p., CAH2Article

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancerDIERAS, Véronique; BACHELOT, Thomas.Targeted oncology. 2014, Vol 9, Num 2, pp 111-122, issn 1776-2596, 12 p.Article

Développement clinique des traitements anti-angiogéniques en 2002 = Clinical development of anti-angiogenic agents in 2002BACHELOT, Thomas; JOUANNEAU, Emmanuel; BLAY, Jean-Yves et al.Bulletin du cancer. 2003, Vol 90, Num 1, pp 19-23, issn 0007-4551, 5 p.Article

Traitements adjuvants : I'exemple du cancer du sein = Adjuvant therapies : the example of breast cancerBACHELOT, Thomas; GUASTALLA, Jean-Paul; RAY-COQUARD, Isabelle et al.La Revue du praticien (Paris). 2008, Vol 58, Num 8, pp 817-819, issn 0035-2640, 3 p.Article

TRAITEMENT ADJUVANT DU CANCER DU SEIN ET THÉRAPIE CIBLÉE : L'ajout du trastuzumab à la chimiothérapie adjuvante diminue de 50 % le risque de récidiveDUFRESNE, Armelle; BACHELOT, Thomas; BLAY, Jean-Yves et al.La Revue du praticien (Paris). 2008, Vol 58, Num 5, pp 477-478, issn 0035-2640, 2 p.Article

Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentationCAMPONE, Mario; JUIN, Philippe; ANDRE, Fabrice et al.Critical reviews in oncology/hematology. 2011, Vol 78, Num 3, pp 195-205, issn 1040-8428, 11 p.Article

THERAPIE GENIQUE PAR TRANSFERT RETROVIRAL DANS LES CELLULES SOUCHES HEMATOPOÏETIQUES, DEVELOPPEMENT DES VECTEURS ET APPLICATION AU CONTROLE DE LA NEOANGIOGENESE TUMORALE = RETROVIRAL-MEDIATED GENE TRANSFER TO THE HEMATOPOIETIC SYSTEM : VECTOR DEVELOPMENT AND POTENTIAL APPLICATION FOR THE CONTROL OF TUMOR ANGIOGENESISBachelot, Thomas; Favrot, Marie.2000, 104 p.Thesis

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast CancerANDRE, Fabrice; BACHELOT, Thomas; SHI, Michael et al.Clinical cancer research (Print). 2013, Vol 19, Num 13, pp 3693-3702, issn 1078-0432, 10 p.Article

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and CapecitabineCORTES, Javier; VAHDAT, Linda; SHUSTER, Dale E et al.Journal of clinical oncology. 2010, Vol 28, Num 25, pp 3922-3928, issn 0732-183X, 7 p.Article

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer : results of the ERASME 3 studyCASSIER, Philippe A; CHABAUD, Sylvie; AGOSTINI, Cecile et al.Breast cancer research and treatment. 2008, Vol 109, Num 2, pp 343-350, issn 0167-6806, 8 p.Article

Inhibition de la voie PI3K dans le cancer du sein ER, positif, HER2 négatif: Des résultats encourageantsBACHELOT, Thomas; HEUDEL, Pierre.Onko +. 2012, Vol 4, Num 28, pp 17-18, issn 2101-9495, 2 p., CAH2Conference Paper

Time-to-event analysis with artificial neural networks: An integrated analytical and rule-based study for breast cancerLISBOA, Paulo J. G; ETCHELLS, Terence A; NEGRIER, Sylvie et al.Neural networks. 2008, Vol 21, Num 2-3, pp 414-426, issn 0893-6080, 13 p.Conference Paper

Breast carcinoma cells promote the differentiation of CD34⁺ progenitors towards 2 different subpopulations of dendritic cells with CD1a^highCD86^-langerin- and CD1a⁺CD86⁺langerin⁺ phenotypesTHOMACHOT, Marie Cécile; BENDRISS-VERMARE, Nathalie; MASSACRIER, Catherine et al.International journal of cancer. 2004, Vol 110, Num 5, pp 710-720, issn 0020-7136, 11 p.Article

Cyclo-oxygénase 2 et cancer du sein. Des concepts biologiques aux essais thérapeutiques = Cyclooxygenase 2 and breast cancerGUASTALLA, Jean-Paul; BACHELOT, Thomas; RAY-COQUARD, Isabelle et al.Bulletin du cancer. 2004, Vol 91, Num MAI, pp S99-S108, issn 0007-4551, NSArticle

Traitement adjuvant du cancer du sein : création d'un arbre de décision thérapeutique au sein d'un réseau de soins = Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer networkBACHELOT, Thomas; RAY-COQUARD, Isabelle; PHILIP, Thierry et al.Bulletin du cancer. 2002, Vol 89, Num 10, pp 897-903, issn 0007-4551Article

LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancerBOUCHEKIOUA-BOUZAGHOU, Katia; POULARD, Coralie; TREILLEUX, Isabelle et al.International journal of cancer (Print). 2014, Vol 135, Num 6, pp 1307-1318, issn 0020-7136, 12 p.Article

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 studyCAMPONE, Mario; BACHELOT, Thomas; BURRIS, Howard A et al.European journal of cancer (1990). 2013, Vol 49, Num 12, pp 2621-2632, issn 0959-8049, 12 p.Article

Patients with metastatic breast cancer leading to CD4⁺ T cell lymphopaenia have poor outcomeTREDAN, Olivier; MANUEL, Manuarii; BLAY, Jean-Yves et al.European journal of cancer (1990). 2013, Vol 49, Num 7, pp 1673-1682, issn 0959-8049, 10 p.Article

Traitements systémiques des métastases cérébrales des cancers du sein: chimiothérapies cytotoxiques et thérapies ciblées = Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapiesBACHELOT, Thomas; LE RHUN, Emilie; LABIDI-GALLY, Intidar et al.Bulletin du cancer. 2013, Vol 100, Num 1, pp 7-14, issn 0007-4551, 8 p.Article

Physicians' preferences for prescribing oral and intravenous anticancer drugs: A Discrete Choice ExperimentBENJAMIN, Laure; COTTE, Frangois-Emery; PHILIPPE, Caroline et al.European journal of cancer (1990). 2012, Vol 48, Num 6, pp 912-920, issn 0959-8049, 9 p.Article

Hormonorésistance des cancers du sein et inhibiteurs de mTOR = Antihormonal therapy in breast cancer and mTOR inhibitorsHEUDEL, Pierre-Etienne; TREDAN, Olivier; RAY-COQUARD, Isabelle et al.Bulletin du cancer. 2011, Vol 98, Num 12, pp 1431-1437, issn 0007-4551, 7 p.Article

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical OutcomeGOBERT, Michael; TREILLEUX, Isabelle; PEREZ, Solène et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 5, pp 2000-2009, issn 0008-5472, 10 p.Article

Traitements anti-VEGF : un emploi universel ? = Are antiangiogenic antibodies universal for solid tumor?RAY-COQUARD, Isabelle; BACHELOT, Thomas; BLAY, Jean-Yves et al.Bulletin du cancer. 2007, Vol 94, Num JUIL, issn 0007-4551, S191-S196, NSArticle

Facteurs pronostiques des neutropénies fébriles : Facteurs de croissance hématopoïétique : nouvelles modalités d'utilisation = Prognostic factors for febrile neutropeniaRAY-COQUARD, Isabelle; BORG, Christophe; BIRON, Pierre et al.Bulletin du cancer. 2006, Vol 93, Num 5, pp 501-506, issn 0007-4551, 6 p.Article

Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cellsSISIRAK, Vanja; VEY, Nelly; MENETRIER-CAUX, Christine et al.International journal of cancer (Print). 2013, Vol 133, Num 3, pp 771-778, issn 0020-7136, 8 p.Article